Internal Medicine, Pulmonary Disease · West Hartford, CT
NPI
1861491839
Since 2005
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
61 S Main St
West Hartford, CT, 06107
Phone (860) 247-2530
Groups this clinician bills Medicare through
Medicare paid, 2024
$140K
1,976 services
Medicare patients, 2024
612
Average age 75
Drug cost, 2024
$10.8M
5,017 prescriptions
Company payments, 2025
$90K
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Tapas Bandyopadhyay was code 99214 (office e&m - established), 688 times for 417 patients. In total Tapas Bandyopadhyay billed 1,976 services in 25 codes, and Medicare paid $140K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-06-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 688 | 417 | $97.09 | $67K |
| 99213 Office E&M - Established | Office | 281 | 198 | $67.72 | $19K |
| 94010 Pulmonary Function Testing | Office | 263 | 213 | $22.52 | $5,924 |
| 94729 Pulmonary Function Testing | Office | 223 | 211 | $46.01 | $10K |
| 94727 Pulmonary Function Testing | Office | 202 | 192 | $36.04 | $7,281 |
| 94060 Pulmonary Function Testing | Office | 74 | 73 | $31.90 | $2,360 |
| 95800 Sleep Study | Office | 71 | 68 | $109.17 | $7,751 |
| 99204 Office E&M - New | Office | 54 | 54 | $118.59 | $6,404 |
| 99205 Office E&M - New | Office | 42 | 42 | $174.98 | $7,349 |
| 99215 Office E&M - Established | Office | 36 | 27 | $142.24 | $5,121 |
By year: 2022 $160K for 2,280 services; 2023 $153K for 2,160 services; 2024 $140K for 1,976 services.
Medicare prescription drug claims, 2024
In 2024, the drug Tapas Bandyopadhyay prescribed most often to Medicare patients was Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter), with 974 prescriptions and refills. In total Tapas Bandyopadhyay wrote 5,017 Medicare prescriptions that cost $10.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 974 | 1,389 | 210 | $892K |
| Prednisone Generic | 554 | 650 | 232 | $2,254 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 475 | 575 | 163 | $9,431 |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 242 | 299 | 60 | $182K |
| Azelastine-Fluticasone Azelastine/Fluticasone | 201 | 224 | 67 | $17K |
| Breo Ellipta Fluticasone/Vilanterol | 163 | 226 | 30 | $89K |
| Opsumit Macitentan | 163 | 177 | 20 | $2.2M |
| Azelastine Hcl Generic | 148 | 261 | 75 | $3,208 |
| Nucala Mepolizumab | 126 | 131 | 12 | $509K |
| Dupixent Pen Dupilumab | 113 | 121 | 13 | $471K |
| Ofev Nintedanib Esylate | 84 | 84 | 11 | $1.1M |
| Cefuroxime Cefuroxime Axetil | 76 | 76 | 66 | $742 |
| Wixela Inhub Fluticasone Propion/Salmeterol | 72 | 102 | 16 | $7,686 |
| Uptravi Selexipag | 63 | 69 | Under 11 | $1.6M |
| Eliquis Apixaban | 62 | 89 | 14 | $51K |
Brand drugs: 2,971 claims; generic drugs: - claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Tapas Bandyopadhyay $90K ($90K in general payments such as food, travel and fees) from 25 companies. The largest payer was Actelion Pharmaceuticals US, Inc. with $21K.
| Company | Payments | Amount |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. JNJ | 39 | $21K |
| GlaxoSmithKline, LLC. GSK | 89 | $21K |
| Mallinckrodt Hospital Products Inc. | 20 | $17K |
| Viatris Specialty LLC | 16 | $11K |
| Genzyme Corporation SNY | 16 | $7,934 |
| Regeneron Healthcare Solutions, Inc. REGN | 15 | $7,097 |
| AstraZeneca Pharmaceuticals LP AZN | 26 | $2,398 |
| Jazz Pharmaceuticals Inc. JAZZ | 9 | $499 |
| Merck Sharp & Dohme LLC MRK | 11 | $310 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 9 | $272 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.